Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23109015 | 0.87 | LMNA (0.38) | LMNAGAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL23103452 | 0.87 | LMNA (0.38) | LMNAGAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL23102957 | 0.87 | LMNA (0.38) | LMNAGAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL23132337 | 0.84 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL23133694 | 0.84 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL23707222 | 0.79 | LMNA (0.34) | LMNAGAATSHR | |
| SCHEMBL23109019 | 0.78 | GAA (0.39) | LMNAGAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL24859533 | 0.78 | GAA (0.39) | LMNAGAATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL25146944 | 0.74 | — | — | |
| SCHEMBL21216998 | 0.73 | HRH3 (0.32) | LMNATSHRALDH1A1SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | LMNA 3355/4885GAA 905/4885TSHR 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.